Ensysce Biosciences
Ensysce Biosciences Reports Third Quarter 2026 Financial Results and Business Highlights
~ Completed Acquisition of Cy Biopharma, Adding Lead Pipeline Asset CY200 for Complex Regional Pain Syndrome ~~ Submitted Phase 2a Protocol for CY200…